Argenx (ARGX +0.83%) already markets Vyvgart Hytrulo for treating generalized myasthenia gravis (gMG) and chronic ...

Bayer (BAYZF) said an experimental imaging agent accurately identified cardiac amyloidosis in a Phase 3 study, producing ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a ...

Anavex Life Sciences (NASDAQ:AVXL) is advancing Alzheimer’s Phase 3 planning with the FDA after submitting its clinical trial ...

Tenax Therapeutics (TENX) said additional analyses from a Phase 3 trial suggest its oral levosimendan treatment may benefit ...

Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC).

A personalized mRNA therapy met two melanoma trial goals, the FDA cleared the first treatment for GSDIa, and Novo tests lower ...

Astellas Pharma (TSE:4503) has started dosing the first patient in a Phase 3 trial of ASP2138 for CLDN18.2-positive and ...

A large multicenter trial testing intravenous arginine as a treatment for acute pain crises in sickle cell patients has ended ...

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study. Combination of ...

A committee said the volrustomig combination was unlikely to reach either of the primary endpoints for the trail, but the company said other Phase 3 volrustomig trials would continue as planned.

Cytokinetics, Incorporated ( CYTK ), a biopharmaceutical company focused on developing muscle-directed therapies, announced positive results from its pivotal Phase 3 ACACIA-HCM trial of aficamten in ...